This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1.-33. (Cancelled)

34. (Previously presented) An isolated nucleic acid comprising the nucleotide sequence as shown in SEQ ID. No. 2.

35.-45. (Cancelled)

46. (Currently Amended) An isolated nucleic acid consisting of ~~which comprises~~ between about 100 and 7000 consecutive nucleotides of SEQ ID NO:2, wherein said nucleic acid contains ~~the nucleotide corresponding to the nucleotide at~~ position 8845 of SEQ ID NO:2.

47. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 250 and 7000 consecutive nucleotides of SEQ ID NO:2.

48. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 750 and 7000 consecutive nucleotides of SEQ ID NO:2.

49. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 1000 and 7000 consecutive nucleotides of SEQ ID NO:2.

50. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 1250 and 7000 consecutive nucleotides of SEQ ID NO:2.

51. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 1500 and 7000 consecutive nucleotides of SEQ ID NO:2.

52. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 1750 and 7000 consecutive nucleotides of SEQ ID NO:2.

53. (Previously presented) An isolated nucleic acid that is a complement of the isolated nucleic acid of claim 46.

54. (Previously presented) The isolated nucleic acid of claim 46, further comprising a label.

55. (Previously presented) The isolated nucleic acid of claim 54, wherein the label is selected from the group consisting of: a radiolabel, an enzyme, a fluorescent compound, streptavidin, avidin, biotin, a magnetic moiety, a metal-binding moiety, an antigen moiety and an antibody moiety.

56. (Previously presented) The nucleic acid of claim 46, wherein the nucleic acid is bound to a solid phase support.

57. (Previously presented) The nucleic acid of claim 46, wherein the nucleic acid is part of a probe array.

58. (Currently Amended) The isolated nucleic acid of claim 46 consisting of ~~which comprises~~ between about 2000 and 7000 consecutive nucleotides of SEQ ID NO:2.

59. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 2500 and 7000 consecutive nucleotides of SEQ ID NO:2.

60. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 3000 and 7000 consecutive nucleotides of SEQ ID NO:2.

61. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 3500 and 7000 consecutive nucleotides of SEQ ID NO:2.

62. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 4000 and 7000 consecutive nucleotides of SEQ ID NO:2.

63. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 4500 and 7000 consecutive nucleotides of SEQ ID NO:2.

64. (Currently Amended) The isolated nucleic acid of claim 46, consisting of ~~which comprises~~ between about 5000 and 7000 consecutive nucleotides of SEQ ID NO:2.

65. - 69. (Cancelled).

70. (New) An isolated nucleic acid consisting of a first nucleic acid operably linked to a second nucleic acid, wherein said first nuleic acid consists of between about 100 and 7000 consecutive nucleotides of SEQ ID NO:2 and contains position 8845 of SEQ ID NO:2, and wherein said second nucleic acid comprises a vector.